MyFinsight
Home
Blog
About
Proceeds from maturities
of marketable...
$67,000K
(-70.39%↓ Y/Y)
Proceeds from the
issuance of common stock...
$3,000K
Proceeds from sale of
marketable securities
$38,000K
(26473.43%↑ Y/Y)
Net cash (used in)
provided by investing...
$44,000K
(-76.97%↓ Y/Y)
Net cash provided by
financing activities
$3,000K
(-96.42%↓ Y/Y)
Effect of exchange rate
changes on cash
$1,000K
(-77.07%↓ Y/Y)
Canceled cashflow
$61,000K
Net (decrease)
increase in cash, cash...
-$49,000K
(-1192.53%↓ Y/Y)
Canceled cashflow
$48,000K
Stock-based compensation
$34,000K
(-56.66%↓ Y/Y)
Accounts payable,
accrued, and other...
$24,000K
(141.28%↑ Y/Y)
Non-cash interest
expense on liabilities...
$22,000K
(-22.49%↓ Y/Y)
Prepaid expenses and
other assets
-$12,000K
(-169.91%↓ Y/Y)
Depreciation and
amortization
$8,000K
(-54.57%↓ Y/Y)
Purchase of marketable
securities
$57,000K
(267.67%↑ Y/Y)
Other
$3,000K
(175.74%↑ Y/Y)
Purchase of property,
plant, and equipment
$1,000K
(-73.57%↓ Y/Y)
Net cash used in
operating activities
-$97,000K
(64.69%↑ Y/Y)
Canceled cashflow
$100,000K
Net loss
-$92,000K
(65.42%↑ Y/Y)
Accounts receivable
$62,000K
(2292.90%↑ Y/Y)
Non-cash royalty revenue
$35,000K
(-29.30%↓ Y/Y)
Other
$5,000K
(106.61%↑ Y/Y)
Inventory
$3,000K
(440.54%↑ Y/Y)
Back
Back
Cash Flow
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)
source: myfinsight.com